Caribou Biosciences Licenses fully human anti-CD371 scFvs

Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced the execution of an exclusive license agreement with Memorial Sloan Kettering Cancer Center (MSK) under which Caribou has rights to fully human anti-CD371 scFvs and intellectual property related thereto in the field of allogeneic CD371-targeted cell therapies developed in the laboratory of Renier Brentjens, M.D., Ph.D. at MSK in collaboration with the Tri-Institutional Therapeutic Discovery Institute (Tri-I TDI).